Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.

Data de publicació: 19/04/2021 Data Ahead of Print: 19/04/2021

Autors de IIS La Fe

Nuria Mancheño Franch

Autor

Autors aliens a IIS La Fe

Conde E
Rojo F
Gómez J
Enguita AB
Abdulkader I
González A
Lozano D
Salas C
Salido M
Salido-Ruiz E
de Álava E

Grups d'Investigació

Unidad de Biomarcadores y Medicina de Precisión (UBYMP)

Leader

Agustín Lahoz Rodríguez

Abstract

The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements in some genes (ie, ALK , ROS1 , RET and NTRK ) have become standard in patients with advanced disease. Since immunohistochemistry is easier to implement and interpret, it is normally used as the screening procedure, while fluorescence in situ hybridisation (FISH) is used to confirm the rearrangement and decide on ambiguous immunostainings. Although FISH is considered the most sensitive method for the detection of ALK and ROS1 rearrangements, the interpretation of results requires detailed guidelines. In this review, we discuss the various technologies available to evaluate ALK and ROS1 genomic rearrangements using these techniques. Other techniques such as real-time PCR and next-generation sequencing have been developed recently to evaluate ALK and ROS1 gene rearrangements, but some limitations prevent their full implementation in the clinical setting. Similarly, liquid biopsies have the potential to change the treatment of patients with advanced lung cancer, but further research is required before this technology can be applied in routine clinical practice. We discuss the technical requirements of laboratories in the light of quality assurance programmes. Finally, we review the recent updates made to the guidelines for the determination of molecular biomarkers in patients with NSCLC.

Dades de la publicació

ISSN/ISSNe:: 0021-9746, 1472-4146
Tipus:: Article
Pàgines:: 145-153
DOI:: 10.1136/jclinpath-2021-207490
PubMed:: 33875457
Factor d'Impacte:: 1,106 SCImago ℠
Quartil:: Q1 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Conde E:: 1 Department of Pathology and Laboratory of Therapeutic Targets & CIBERONC, HM Hospitales, Madrid, Spain
Rojo F:: 2 Department of Pathology, Hospital Universitario Fundacion Jiménez Díaz, Madrid, Spain.
Gómez J:: 3 Department of Pathology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain.

4 Instituto de Investigación Sanitaria Valdecilla IDIVAL, Universidad de Cantabria, Santander, Cantabria, Spain.
Enguita AB:: 5 Department of Pathology, Clínica Dermatológica Internacional, Madrid, Spain.
Abdulkader I:: 6 Department of Pathology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.
González A:: 7 Department of Pathology, Hospital Álvaro Cunqueiro, Vigo, Spain.
Lozano D:: 8 Department of Pathology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
Mancheno, Nuria:: 9 Department of Pathology, La Fe University and Polytechnic Hospital, Valencia, Comunidad Valenciana, Spain.
Salas C:: 10 Department of Pathology, Hospital Universitario Puerta del Hierro Majadahonda, Majadahonda, Madrid, Spain.
Salido M:: 11 Department of Pathology, Hospital del Mar, Barcelona, Spain.
Salido-Ruiz E:: 12 Department of Pathology, Hospital Universitario de Canarias, La Laguna, Canarias, Spain.
de Álava E:: 13 Department of Pathology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.